<DOC>
	<DOCNO>NCT01419769</DOCNO>
	<brief_summary>The Xlumena AXIOS Stent Delivery System investigational device USA , study conduct Investigational Device Exemption ( IDE ) grant US Food Drug Administration ( FDA ) . The study design prospective , multi-center , non-blinded , single-arm ( nonrandomized ) study . Up 10 site United States , European Community and/or Japan enroll total 24 patient . A majority patient enrol United States . Patients follow ( approximately ) 30 day and/or 60 day depend upon pseudocyst resolution confirmation , 1-week post-stent removal , possibly 3 6 month post-stent removal .</brief_summary>
	<brief_title>AXIOS Stent &amp; Delivery System Study</brief_title>
	<detailed_description>OBJECTIVE : To demonstrate safety effectiveness Xlumena AXIOS Stent Delivery System endoscopic drainage pancreatic pseudocysts patient symptomatic pancreatic pseudocysts great equal 6 cm ( ≥6cm ) diameter , ≥ 70 % fluid content adherent bowel wall . STUDY DESIGN : Prospective , multi-center , non-blinded , single-arm ( nonrandomized ) study KEY ENDPOINTS : Safety : The safety endpoint freedom major complication duration 1-week post-stent removal study period , define : 1 . Access site-related bleeding require transfusion ; 2 . Access site-related infection require intravenous intramuscular antibiotic and/or extended hospitalization ; 3 . Surgery access-site related perforation ; 4 . Stent migration/dislodgement pseudocyst enteral lumen ; 5 . Tissue injury , define ulceration submucosa site stent implant observe persist 1-week post-stent removal . 6 . Serious adverse event classify implant-associated implant/endoscopic procedure-associated ; Effectiveness : 1 . Stent lumen patency 30 day and/or 60 day 2 . Stent removability 30 day and/ 60 day . 3 . Technical success , define : placement AXIOS stent use AXIOS delivery system removal AXIOS stent use standard endoscopic snare . 4 . Clinical success , define : least 50 % decrease pseudocyst size , base radiographic analysis , 30 day and/or 60 day . PATIENT POPULATION : Patients 18 75 year age , suitable transluminal drainage symptomatic pancreatic pseudocysts great equal 6 cm diameter adherent bowel wall candidate study treatment . FOLLOW-UP SCHEDULE : Clinical follow-up evaluation study endpoint conduct 30 day and/or 60 day , 1 week post stent removal possibly 3 6 month post stent removal . PLANNED NUMBER OF PATIENTS , SITES &amp; REGIONS : The target enrollment study 24 subject . Study conduct 10 investigational site United States , Japan and/or European Community . A majority patient enrol United States .</detailed_description>
	<mesh_term>Pancreatic Pseudocyst</mesh_term>
	<criteria>( patient must meet criterion ) 1 . Age 18 75 year old , male female . 2 . Eligible endoscopic intervention . 3 . Acceptable candidate endoscopic transluminal pancreatic pseudocyst drainage 4 . Symptomatic pancreatic pseudocyst follow characteristic : Greater equal 6 cm size ( base upon maximum crosssectional area CT scan ) , Adherent bowel wall , ≥70 % fluid content 5 . Patient understand study requirement treatment procedure provide write Informed Consent use form approve local Institutional Review Board Ethics Committee studyspecific test procedure perform . 6 . Patient willing comply specify followup evaluation , include willingness undergo pre/post CT imaging study . ( patient meet criterion exclude study ) 1 . &lt; 18 &gt; 75 year age 2 . Pancreatic pseudocysts follow characteristic : Require nasocystic drainage , &lt; 69 % fluid content 3 . The fluid collection drain immature pseudocyst 4 . The fluid collection drain cystic neoplasm 5 . The fluid collection drain pseudoaneurysm 6 . The fluid collection drain duplication cyst 7 . The fluid collection drain noninflammatory fluid collection 8 . There one pseudocyst require drainage 9 . Abnormal coagulation : INR &gt; 1.5 correctable presence bleed disorder platelet &lt; 50,000/mm3 10 . Altered anatomy preclude physician 's ability deliver stent ( decision case case basis ) . 11 . Intervening gastric varix vessel within one centimeter radius needle ( visible use endoscopy endoscopic ultrasound ) 12 . Any prior true anaphylactic reaction contrast agent , nitinol ( nickel titanium ) , silicone material contact patient . 13 . Female childbearing potential positive pregnancy test prior procedure intend become pregnant study . 14 . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>symptomatic pancreatic pseudocyst</keyword>
	<keyword>pancreatic pseudocyst</keyword>
	<keyword>transluminal drainage</keyword>
	<keyword>minimally invasive</keyword>
	<keyword>Nitinol stent</keyword>
	<keyword>transmural endoscopic drainage</keyword>
	<keyword>catheter base</keyword>
</DOC>